Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
To read the full story
Related Article
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
- Drug Makers Calling Off Welcoming Ceremonies for New Hires over Coronavirus
March 11, 2020
- Sawai Refrains from Sales Reps' Doctor Visits Through March 13
March 4, 2020
- Pfizer Sales Reps Told to Avoid Doctor Visits, Stay at Home amid Coronavirus Woes
March 2, 2020
- Japan Drug Makers Fearing Manufacturing Crisis as Coronavirus Spreads
February 27, 2020
- Drug Makers in Japan Upping Coronavirus Measures; Takeda Switches to Online Interviews for New R&D Hires
February 26, 2020
- Astellas, MSD Follow Suit to Boost Measures to Protect Employees from Coronavirus Infection
February 21, 2020
- Drug Makers in Japan Urging Staffers to Work at Home, Shun Rush-Hour Commuting amid Coronavirus Fears
February 19, 2020
BUSINESS
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
- Toho Backs AI Startup Developing Laxative-Free Colonoscopy
November 16, 2026
- KM Biologics Files Japan’s Potential First Therapy for Factor X Deficiency
November 16, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





